ABVC BioPharma (ABVC) Competitors $0.86 +0.06 (+7.63%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.86 +0.01 (+0.58%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVC vs. INKT, OVID, PLUR, SNYR, ELEV, PULM, TNXP, MRNS, IRD, and VRCAShould you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include MiNK Therapeutics (INKT), Ovid Therapeutics (OVID), Pluri (PLUR), Synergy CHC Corp. (Uplisting) (SNYR), Elevation Oncology (ELEV), Pulmatrix (PULM), Tonix Pharmaceuticals (TNXP), Marinus Pharmaceuticals (MRNS), Opus Genetics (IRD), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical products" industry. ABVC BioPharma vs. MiNK Therapeutics Ovid Therapeutics Pluri Synergy CHC Corp. (Uplisting) Elevation Oncology Pulmatrix Tonix Pharmaceuticals Marinus Pharmaceuticals Opus Genetics Verrica Pharmaceuticals MiNK Therapeutics (NASDAQ:INKT) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, community ranking, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk. Which has stronger valuation & earnings, INKT or ABVC? ABVC BioPharma has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$22.46M-$2.92-3.12ABVC BioPharma$509.79K21.76-$10.52M-$0.86-0.99 Is INKT or ABVC more profitable? MiNK Therapeutics has a net margin of 0.00% compared to ABVC BioPharma's net margin of -1,619.65%. MiNK Therapeutics' return on equity of 0.00% beat ABVC BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -189.14% ABVC BioPharma -1,619.65%-104.94%-56.81% Does the media prefer INKT or ABVC? In the previous week, MiNK Therapeutics had 6 more articles in the media than ABVC BioPharma. MarketBeat recorded 8 mentions for MiNK Therapeutics and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.44 beat MiNK Therapeutics' score of 0.45 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Overall Sentiment MiNK Therapeutics Neutral ABVC BioPharma Positive Which has more risk and volatility, INKT or ABVC? MiNK Therapeutics has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Does the MarketBeat Community believe in INKT or ABVC? MiNK Therapeutics received 17 more outperform votes than ABVC BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformMiNK TherapeuticsOutperform Votes1777.27% Underperform Votes522.73% ABVC BioPharmaN/AN/A Do institutionals and insiders hold more shares of INKT or ABVC? 2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 20.6% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 11.9% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate INKT or ABVC? MiNK Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 311.64%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MiNK Therapeutics is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryMiNK Therapeutics and ABVC BioPharma tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVC vs. The Competition Export to ExcelMetricABVC BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.09M$6.94B$5.64B$7.83BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-0.997.1623.1318.64Price / Sales21.76222.43388.4791.24Price / CashN/A65.6738.1634.64Price / Book0.846.396.884.23Net Income-$10.52M$142.12M$3.20B$247.06M7 Day Performance23.91%-4.85%-2.80%-2.15%1 Month Performance23.90%-7.25%1.74%-5.71%1 Year Performance-34.73%-8.77%9.80%-0.84% ABVC BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVCABVC BioPharma1.3935 of 5 stars$0.86+7.6%N/A-34.4%$11.16M$509,788.00-1.0030Upcoming EarningsShort Interest ↓Positive NewsINKTMiNK Therapeutics2.4188 of 5 stars$8.52+0.4%$37.50+340.1%-0.6%$33.77MN/A-2.1830OVIDOvid Therapeutics4.5056 of 5 stars$0.47+7.4%$3.20+586.5%-88.5%$33.10M$566,000.00-0.9960Analyst RevisionPLURPluri0.9807 of 5 stars$4.72+2.4%N/A-31.9%$33.03M$678,000.00-0.84150Short Interest ↓Positive NewsSNYRSynergy CHC Corp. (Uplisting)3.5867 of 5 stars$3.58+0.8%$10.00+179.3%N/A$31.16M$26.01M0.0040ELEVElevation Oncology2.4238 of 5 stars$0.53-1.3%$6.83+1,199.4%-94.9%$31.14MN/A-0.6440PULMPulmatrix0.2115 of 5 stars$8.39-0.8%N/A+310.9%$30.62M$10.01M-3.1820Earnings ReportPositive NewsTNXPTonix Pharmaceuticals2.4508 of 5 stars$16.28+8.5%$1,100.00+6,656.8%-96.6%$30.43M$11.29M0.0050Short Interest ↑Gap DownMRNSMarinus Pharmaceuticals2.3345 of 5 stars$0.55-0.2%$4.79+771.6%-93.9%$30.32M$30.99M-0.22110Analyst ForecastNews CoverageIRDOpus Genetics2.3129 of 5 stars$0.94+0.7%$8.00+749.6%N/A$29.72M$8.38M-0.8614VRCAVerrica Pharmaceuticals4.2442 of 5 stars$0.65+21.1%$9.50+1,360.4%-92.7%$29.66M$7.57M-0.3640 Remove Ads Related Companies and Tools Related Companies MiNK Therapeutics Competitors Ovid Therapeutics Competitors Pluri Competitors Synergy CHC Corp. (Uplisting) Competitors Elevation Oncology Competitors Pulmatrix Competitors Tonix Pharmaceuticals Competitors Marinus Pharmaceuticals Competitors Opus Genetics Competitors Verrica Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVC) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABVC Stock Free ABVC Stock Alerts